Navigation Links
Hormonal male contraception reversible after few months for all men

With hormonal male contraception likely to be available in the near future, results of a study in this week's issue of THE LANCET highlight how such contraception is reversible within a few months.

Currently available male contraceptive methods (condoms, withdrawal, and vasectomy) are not acceptable to many couples because they are either not sufficiently reliable or not easily reversible. In a similar way to ovulation suppression by hormone treatment in women, sperm production can be fully inhibited by androgen or androgen-progestagen treatment combinations in men. With such hormone treatment, azoospermia (no sperm in ejaculate) or severe oligozoospermia (less than 3 million sperm per mL of semen), which is sufficient for contraceptive purposes, can be achieved. Currently, a large phase III study with an androgen treatment and a large, multicentre phase II study of androgen-progestagen combinations are being completed in China and Europe, respectively.

Peter Liu from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), who is currently located at the ANZAC Research Institute, University of Sydney, Australia, and colleagues analysed data from individual participants in 30 studies published in 1990?005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility.

Data were available for around 1500 men. The average time for sperm recovery to 20 million/mL was 3? months. Various factors were associated with higher rates of recovery including older age, Asian origin, shorter treatment duration, and higher sperm concentrations at baseline. Although these factors modulated the speed of recovery, spermatogenesis recovered to levels compatible with fertility in all men.

Dr Liu and colleagues comment: "Our data provide strong assurance that the previously described eff icacy of hormonal male contraceptives is coupled with highly predictable recovery to semen characteristics that are compatible with fertility. These findings thereby increase the promise of new contraceptive drugs allowing men to share more fairly the satisfaction and burden of family planning."


'"/>

Source:Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)


Related biology news :

1. Emergency contraception fails to halt abortions
2. Male contraception: One door opens, another closes
3. Cancer cells suppress large regions of DNA by a reversible process that can be tackled
4. Rewind, please: Nature paper shows that cell division is reversible
5. First-degree fetal heart block may be reversible
6. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
7. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
8. Stem cell treatment improves mobility after spinal cord injury
9. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
10. New type of rejection blocker protects kidneys after transplant
11. Hurricane aftermath: Infectious disease threats from common, not exotic, diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
Breaking Biology Technology: